Lymphovascular invasion is associated with poor long-term outcomes in patients with pT1N0-3 or pT2-3N0 remnant gastric cancer: a retrospective cohort study
By: Sumiyoshi, Shutaro, Ohashi, Takuma, Kubota, Takeshi, Nishibeppu, Keiji, Owada, Kaho, Kiuchi, Jun, Shimizu, Hiroki, Arita, Tomohiro, Iitaka, Daisuke, Yamamoto, Yusuke, Konishi, Hirotaka, Morimura, Ryo, Watanabe, Kenji, Kuriu, Yoshiaki, Shiozaki, Atsushi, Ikoma, Hisashi, Fujiwara, Hitoshi, Yamaoka, Nobuki, Otsuji, Eigo

BioMed Central
2024-04-05; doi: 10.1186/s12957-024-03371-z

Abstract

Background

Lymphovascular invasion (LVI) is a poor prognostic factor in various malignancies. However, its prognostic effect in remnant gastric cancer (RGC) remains unclear. We examined the correlation between LVI and disease prognosis in patients with T1N0-3 or T2-3N0 RGC in whom adjuvant chemotherapy was not indicated and a treatment strategy was not established.

Methods

We retrospectively analyzed patients with T1N0-3 and T2-3N0 RGC who underwent curative surgery at the Kyoto Prefectural University of Medicine between 1997 and 2019 and at the Kyoto Chubu Medical Center between 2009 and 2019.

Results

Fifteen of 38 patients (39.5%) with RGC were positive for LVI. Patients with LVI had a significantly poorer prognosis for both overall survival ([OS]: P = 0.006) and recurrence-free survival ([RFS]: P = 0.001) than those without LVI. Multivariate analyses using the Cox proportional hazards model revealed LVI as an independent prognostic factor affecting OS (P = 0.024; hazard ratio 8.27, 95% confidence interval:1.285–161.6) and RFS (P = 0.013; hazard ratio 8.98, 95% confidence interval:1.513–171.2).

Conclusions

LVI is a prognostic factor for patients with T1N0-3 or T2-3N0 RGC. Evaluating LVI may be useful for determining treatment strategies for RGC.







Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements